We are international
Donate
• treatment options TEXT SIZE   
novel therapies    back

IMF REPORTS POSITIVE SHIFT IN TREATMENT PARADIGM FOR PATIENTS
Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID® with Low Dose Steroids in Myeloma
05.15.07

Be the first to comment

 related articles